- Litigation / Dispute Resolution (19)
- Healthcare (18)
- Company/Commercial (17)
- Corporate (16)
- Intellectual Property (16)
- Banking / Finance (9)
- Information Technology (9)
- Regulatory and compliance (8)
- Employment (6)
- Real Estate (5)
- Clinical/Medical Negligence (4)
- Commodities (4)
- Energy (4)
- Crime (3)
- Financial services (3)
- Insurance/reinsurance (3)
- Media/Entertainment/Sport (3)
- Tax (3)
- Transport (Including aviation and shipping) (3)
- Competition/EU (2)
- Environment (2)
- Funds (2)
- Privacy and reputation (2)
- Private Equity (2)
- Telecoms (2)
- Agriculture (1)
- Licensing/Gaming/Betting (1)
- Pensions (1)
- Personal tax / Trusts (1)
- Planning (1)
- Public Sector/Local Authority (1)
Sort By: Newest first | Oldest first
DLA Piper has advised Pfizer on the $635m (£405m) acquisition of commercial vaccines from Baxter.
DLA Piper has acted for China’s largest pharmaceutical company on the issuance of HK$5.5bn of new shares.
DLA Piper has advised Australian Securities Exchange-listed REVA Medical Inc on the issue of $25m (£15.8m) of convertible notes and also 8,750,000 options to an international investor consortium.
DLA Piper advised Neothetics in the pricing of its initial public offering of 4,650,000 shares of its common stock at a public offering price of $14 per share.
DLA Piper and Gallastegui Lozano are to combine in Mexico City. Locally, the combined firm will adopt the name DLA Piper Gallastegui y Lozano.
Health Alert — Gray v Richards; Psychology Board of Australia v G; health insurance legislation amendment; and more
DLA Piper has released the 20 October 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
DLA Piper has advised Synergy Health on its recommended combination with STERIS Corporation.
This guide provides sound, practical advice on the relevant laws and regulations for foreign companies looking to invest in Australia.
DLA Piper has recruited Mark Riera as a litigation partner in its Los Angeles office. Riera is a trial and appellate lawyer with experience in a range of industries.
In D’Arcy v Myriad Genetics, five judges of the Full Federal Court of Australia have confirmed that isolated nucleic acid sequences are patentable subject matter in Australia.
Debates on the laws and regulations that will govern biosimilar products have been raging for some time.
Intellectual Property and Technology News — state biosimilars laws are evolving; surviving a trademark opposition challenge; and more
DLA Piper has released issue 23 of its Intellectual Property and Technology News, which reports on worldwide developments in IP and technology law.
Life Sciences Spotlight: Chinese regulatory enforcement action not slowing down; patent strategies and loyalty discounts; and more
DLA Piper has released the fourth edition of Life Sciences Spotlight, which discusses developments in the sector across the Asia-Pacific region.
Life Sciences Spotlight: Chinese regulatory enforcement action showing no signs of slowing down; and more
Welcome to the fourth edition of Life Sciences Spotlight.
European Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine
The European Commission has imposed fines totalling €427.7m on the French pharmaceutical company Servier and five producers of generic medicines.
DLA Piper has announced that Shane Albright has joined the firm’s corporate and finance practice as a partner in the Silicon Valley office.
Antitrust and competition enforcement is changing fast: our report for multinationals from three global conferences
The world of antitrust/competition enforcement is changing more rapidly than ever. This evolving environment presents new challenges for companies.
Amy Jensen Cunniffe has joined DLA Piper’s government affairs and healthcare public policy and regulatory practices as a senior policy adviser in Washington DC.
DLA Piper has advised Parnell Pharmaceuticals Holdings (PARN) in its initial public offering on NASDAQ.
DLA Piper has announced that Ben Boyd and Mary Gately have been named co-managing partners of the Washington DC office.